
Marc G. Ghany, MD, discusses oral agents for the treatment of chronic hepatitis B, their potency, and barriers to resistance and how this impacts the selection of initial treatment regimens.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount the results of clinical studies of oral treatments for HBeAg-positive, HBeAg-negative, and HBV treatment–naive patients
- Describe the differences in potency between currently available oral agents and highlight the importance of potency in prevention of HBV resistance
- Identify management strategies that may reduce the risk of hepatitis B virus resistance
Abstract